Skip to main content
. 2022 Feb 10;29(5):3338–3346. doi: 10.1016/j.sjbs.2022.02.009

Table 2.

Technologies used in HSCs transplantation.

Total Multiple Sclerosis Systemic Sclerosis Rheumatoid arthritis Juvenile idiopathic arthritis Systemic Lupus Erythematosus Immune Thrombocytopenia P-value
Source of stem cell 0.0001
BM 54 12 2 1 23 11 2
BM ± PB 419 138 69 69 28 51 8



Mobilization of peripheral blood 0.0001
GF 89 15 7 41 9 2 4
Cy ± GF 289 112 59 28 13 43 2
Others 42 11 4 0 6 6 2



Conditioning 0.0001
Cy 117 2 38 63 0 1 3
Cy + ATG + drugs 127 22 23 3 21 34 3
Cy + radiation 48 13 2 0 19 12 0
Bu + Cy 24 16 0 2 1 1 1
BEAM + ATG 92 82 1 0 0 4 1
Other 23 3 1 1 4 3 2



Intensity 0.0001
High 72 29 2 2 20 13 1
Intermediate 225 105 25 3 23 40 4
Low 134 4 38 64 2 2 5



In vitro purging 0.0001
CD 34 selection 213 60 46 38 21 24 4
CD selection ± T B depletion 36 12 9 2 5 2 1
T/B depletion 17 4 1 0 11 0 1
Chemotherapy 19 3 0 1 5 1 1

ATG: anti-thymocyte globulin. Cy: cyclophosphamide. Bu: busulfan. BEAM: polychemotherapy. T/B: T/B cell depletion.